“Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea”, J of Skin, vol. 4, no. 5, p. s54, Sep. 2020, doi: 10.25251/skin.4.supp.53.